Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has announced that it is leveraging its proprietary CobaCyte drug delivery platform technology to create new formulations of active pharmaceutical agents.
Subscribe to our email newsletter
Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane, its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane in a standard mouse tumor model.
At a dose of Cobraxane which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles.
Cobraxane, injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane. Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane.
Access Pharmaceuticals president and CEO Jeffrey B. Davis it is known that certain diseased cells, notably cancer, have an elevated demand for certain vitamins, including vitamin B12, making its Cobalamin platform technology compelling for reformulations of cancer-killing agents nearing the end of their patent life.
"As pharmaceutical companies seek ways to create new formulations for the active drugs, and extend their patent runway, we believe our CobaCyte™ platform technology can be the necessary enabling technology," Davis added.
Access’ worldwide-exclusive patented Cobalamin technology utilizes the body’s natural vitamin B12 uptake mechanisms to facilitate absorption of pharmaceuticals and other active agents via a ‘Trojan horse’ mechanism.
Cobalamin transport can be amplified by the use of proprietary nanoparticles or polymers that can greatly amplify uptake. This technology platform provides Access with the ability to develop different formulations with improved benefits for various disease applications.
The company believes its Cobalamin drug delivery technology has broad application to proteins, small molecule drugs, hormones and potentially sRNAi therapeutics, and has recently accelerated its corporate partnering efforts around the technology.
Abraxane is a registered trademark of Celgene.